Specify a stock or a cryptocurrency in the search bar to get a summary
Medincell SA
MDCLFMedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France. Address: 3 rue des Frères Lumière, Jacou, France, 34830
Analytics
WallStreet Target Price
18.39 EURP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MDCLF
Dividend Analytics MDCLF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MDCLF
Stock Valuation MDCLF
Financials MDCLF
Results | 2019 | Dynamics |